Background: Transmission of hepatitis B virus (HBV) via hepatitis B surface antigen (HBsAg) 
Introduction:
In Egypt, Current mortality due to liver disease, including liver cirrhosis and cancer, is over 40,000/year and is increasing annually. It is estimated that approximately 400 millionpeople worldwide are chronically infected with HBV,where Egypt is considered as an area of intermediateendemicity (29).Hepatitis B virus (HBV) is easily transmitted byblood products as both cellular and plasma-derivedcomponents may be infected (6) . Transfusion-transmittedHBV played a major role in the spread of this infectionsome decades ago all around the world, and is still athreat in developing countries, where the prevalenceof this infection is higher and the donor selection andscreening procedures are less tight (6, 18) .
Occult hepatitis B infection (OBI) is defined by the presence of HBV DNA in the liver tissue of individuals who test negative for HBsAg, regardless of the detection of HBV DNA in serum (23) .
OBI was reported for the first time almost 30 years ago in a case report of HBV infection through blood transfusion by an antibody to hepatitis B core antigen (anti-HBc) only positive donor (33) .
In most developed countries,nucleic acid amplification testing (NAT) has beenintroduced along with serological testing for HBV, hepatitis C virusand human immunodeficiency virus in order to enhanceblood safety (8, 24, 1) .In contrast, developing countries with limited resources cannot implement NAT for screening of all donor collected bloodand are relying on proper donor selection which is complemented by sensitive cost effective serological screening tests to exclude the transmission of infective agents (19, 21) .
In Egypt,screening for HBsAg is the only mandatory screening test for the detection of Hepatitis B virus (HBV) infection in blood banks (29) . Only four qualified blood centresare already implementing NAT in Egypt, and these are National Cancer Institute (NCI)blood bank, blood bank of Nasser Institute, blood bank of EL-Shabrwishy Hospital(Private hospital) and the EgyptianOrganization for biological products andvaccines (VACCERA) blood bank (27) . Given the constrained economy, lack of appropriate infrastructure and inadequate trained personnel limitits implementation in all blood banks (25, 10) .New cost-effective strategies and stringent donor selection implementation are very important measures to ensure blood safety in resource-limited countries.
Unlike HCV, HBV cannot be cured, and the treatment for it is life-long.National Committee for 
Materials and Methods:
Blood samples
The present study included 800samples from blood donors negative for anti-hepatitis C antibody (HCV), anti-human immunodeficiency virus (HIV), and HBsAgcollected over a period of 6 months (from April 2014 to September 2014)inFayoum university hospital blood bank.
Detection of Serologic Markers
Serum HBV total anti-HBc was performed by ELISA technique,Monoliza Anti-hepatitis B core 
Results:

Serological results
All participants were negative for HBsAg. 99/800 (12.37 %) of blood donors were negative for
HBsAg and positive for anti-HBc. Anti-HBs antibody was detected in 78/99(78.78%) of HBsAg negative and anti-HBc positive samples, with serum levels > 10 IU/L.
Molecular findings
Detection of HBV-DNA was performed on all samples that were negative for HBsAg and positive for anti-HBc antibody only by use of real time PCR technique. HBV-DNA was detected in 2 out of 21 anti-HBc positive specimens (9.52%).
Discussion:
OBI is defined as the presence of HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals who tested negative for HBsAg (26) . Occult HBV is transmissible by blood transfusion, although the transmission rate is considered to be very low.
The clinical outcome of OBI transmission mainly depends on the immune status and copies of HBV DNA in blood products of the recipient (30) .At present, HBsAg detection is the only obligatory diagnostic screening test for HBV infection in blood transfusion centers in Egypt (25, 10) . We examined 800HBsAg negative sera obtained from healthy blood donors and found that 12.37% of them were positive for anti-HBc, which is comparable to two previous Egyptian studies with a prevalence of 14.2% and 10.9 % of HBsAg negative volunteer blood donors (29, 11) .The study is also comparable to the older anti-HBc prevalence rates reported among HBsAgnegative blood donors in India; 10.01% (19) and 11.2% in Syria (21) , respectively.
The prevalence of anti-HBc only in Europe and North America is overall quite low. A prevalence of 0.07% in the UK and 1.5% in Germany was reported (2, 13) . In areas of higher HBV infection prevalence about 20%-70% of subjects are positive for anti-HBc antibody (7) .
In our study the overall prevalence of occult HBV infection in healthy blood donors was 9.52% among anti-HBc positive alone individuals. Different results have been reported in other studies regarding the rate of OBI in blood donors. These differences in the occult HBV prevalence may be attributed to race and ethnicity, geographical area and the HBV subtypes (3, 14) . The frequency of HBV-DNA detected in HBsAg negative samples also variesconsiderably according to the prevalence of the infection. In Northern countries where the prevalence of chronic infection is less than 1%, no more than 5% of HBsAg negative /anti-HBc positive blood donor samples contain HBV-DNA (2, 16) .In contrast, higher OBI levels in HBsAg-negative blood were recorded in several published reports. In India, the prevalence was 24% (22) and in a published study from Korea, 16% of the studied sample was found to be positive for OBI (15) . . The use of HBV anti core testing to eliminate theresidual transfusion risk of transmission of HBV hasnot been evaluated in Egypt.
Conclusion:
One of the main mechanisms for OBI transmission is most likely through infected blood and its components and our findings revealed that OBI exists among Egyptian blood donors. Screening 
